Allergan Appoints New President
Allergan, Inc., a multi-specialty healthcare company, announced the appointment of Douglas S. Ingram as President. He will lead the company’s global commercial operations. With more than 25 years of experience, and 17 years in Allergan, Ingram has a strong background in healthcare in the USA and internationally. Chairman David E.I. Pyott was quoted saying, “During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business.” Over the span of his tenure at Allergan, Ingram served under various capacities leading Global Legal Affairs, Compliance, Internal Audit, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and the Public Relations Department.
McCann Health Strengthens North American Operations
McCann Health announced a series of moves aimed at bolstering the capabilities of its North American operations. CEO John Cahill announced the promotion of Marci Piasecki to the Regional Director of McCann Health North America. Cahill was quoted saying, “Marci is an extraordinary leader and pillar of McCann Health. Year after year, whatever the business environment, Marci has proven herself again and again by growing her business through her exemplary capabilities and by attracting and retaining a remarkably talented staff and roster of clients.” To which Marci added,” I am honored and eager to assume this new level of leadership within McCann Health. Equally importantly, I am excited for my colleagues who have worked alongside me to provide our network with their expanded responsibilities.”
Bristol-Myers Squibb, a global biopharmaceutical company, announced that its Board of Directors elected Dinesh C. Paliwal as a member of the Committee on Directors and Corporate Governance. He is currently the Chairman and President and Chief Executive Officer of Harman International Industries, Inc.
Cubist Pharmaceuticals, a biopharmaceutical company, announced the appointment of Dr. Lorianne Masouka as the Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs. Masouka brings 25 years of global medical and development experience, including a position as Senior VP at Nektar Therapeutics.
Specialty drug maker Forest Labs, announced the appointment of Vincent Intrieri to its board, expanding it to 11 directors. Having worked with various Carl Icahn entities since 1998, Intrieri is on several boards, including the Chesapeake Energy Corp.
Galectin Therapeutics, announced the appointment of Jack W. Callicut as the Chief Financial Officer. Callicut will play a key role in shaping the corporate strategy as the company advances its key product assets in the clinic. With over 22 years of experience in public and private companies, Callicut was previously CFO of Reach Health, Inc., a telemedicine firm.
Intouch Solutions, a privately held marketing agency specializing in solutions for the pharmaceutical and healthcare industries, announced the appointment of Jeff Huggins as Senior Technology Strategist. Huggins will oversee the development of new technology solutions for clients. Huggins served as VP at MMGY Global. With more than 30 years of experience behind him, Intouch Solutions believes he brings a wealth of strategic technical planning knowledge.
LehmanMillet, one of the only agencies dedicated to serving healthcare organizations that are changing the standards of care, announced a set of new hires and promotions across its three verticals: pharmaceuticals, devices and diagnostics. Santa Ana new hire Greg Raiser is VP and Senior Art Director. The company’s Boston office hired Brian McNamara as Senior Account Manager, and promoted Ben Beckley to Vice President, Account Director.
Lexicon, a biopharma-ceutical company focused on discovering breakthrough treatments for human disease, announced the appointment of John Northcott as VP, Marketing. In his new position, Northcott will be responsible to develop the commercial functions for Lexicon and lead the commercialization of the company’s products. His initial focus will be on telotristat etiprate for carcinoid syndrome.
Mylan Specialty, a global pharmaceutical company, announced the appointment of Roger Graham as President. Prior to Mylan, Graham worked at Advandx, a private developer of in-vitro diagnostic tests in the infectious disease area.
Novira Therapeutics, a company focused on the discovery of the first-in-class antiviral therapeutics for the treatment of chronic HBV infection, announced an expansion of its senior management team, with the hire of Klaus Klumpp, PhD as Vice President, Discovery Research. Dr. Klumpp’s career spans 15 years at Roche, as the global head of virology discovery.
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc., a specialty bio-pharmaceutical company, announced that it has formed an Office of the President consisting of Richard Crowley as Co-President and Chief Operating Officer; John P. Hamill as Co-President and Chief Financial Officer, and Philip K. Yachmetz, as Co-President and Chief Business Officer. The company also announced that Louis Ferrari, President, Chief Executive Officer and Director is leaving the company to pursue other interests.
Tris Pharma, a speciality pharmaceutical company focused on developing innovative drug delivery technologies, announced Janet Penner as the President of its new generic pharmaceuticals business. Janet comes with 15 years of leadership roles within the generic pharmaceuticals industry, which will tremendously help the company in evolving its overall strategic vision.
Qu Biologics, a private clinical stage biopharmaceutical company that develops Site Specific Immunomodulators (SSI), announced that it is pleased to welcome Robert Pelzer to the company’s Board of Directors. Prior to this, Peizer was the President of Novartis Corporation based in New York City.